Literature DB >> 26369535

A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease.

Alexandre Aubourg1, Laurence Picon1, Thierry Lecomte1,2, Theodora Bejan-Angoulvant2,3, Gilles Paintaud2,4, David Ternant5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369535     DOI： 10.1007/s00228-015-1942-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

Authors:  David Ternant; Denis Mulleman; Danielle Degenne; Stéphanie Willot; Jean-Maurice Guillaumin; Hervé Watier; Philippe Goupille; Gilles Paintaud
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

2.  Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.

Authors:  Zhenhua Xu; Kathleen Seitz; Adedigbo Fasanmade; Joyce Ford; Paul Williamson; Weichun Xu; Hugh M Davis; Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2008-04-09       Impact factor: 3.126

3.  Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Joyce Ford; Danika Hernandez; Jewel Johanns; Chuanpu Hu; Hugh M Davis; Honghui Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

4.  Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.

Authors:  David Ternant; Emilie Ducourau; Aleth Perdriger; Anca Corondan; Benoît Le Goff; Valérie Devauchelle-Pensec; Elisabeth Solau-Gervais; Hervé Watier; Philippe Goupille; Gilles Paintaud; Denis Mulleman
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

5.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Marion Blank; Honghui Zhou; Hugh M Davis
Journal:  Clin Ther       Date:  2011-07-07       Impact factor: 3.393

6.  Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.

Authors:  David Ternant; Denis Mulleman; Francine Lauféron; Céline Vignault; Emilie Ducourau; Daniel Wendling; Philippe Goupille; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

7.  Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.

Authors:  Iris Dotan; Yulia Ron; Henit Yanai; Stuart Becker; Sigal Fishman; Lior Yahav; Merav Ben Yehoyada; Diane R Mould
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

8.  Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Authors:  David Ternant; Zahir Berkane; Laurence Picon; Valérie Gouilleux-Gruart; Jean-Frédéric Colombel; Matthieu Allez; Edouard Louis; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

9.  Infliximab pharmacokinetics in inflammatory bowel disease patients.

Authors:  David Ternant; Alexandre Aubourg; Charlotte Magdelaine-Beuzelin; Danielle Degenne; Hervé Watier; Laurence Picon; Gilles Paintaud
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681
  9 in total
  5 in total

1.  The underlying inflammatory chronic disease influences infliximab pharmacokinetics.

Authors:  Christophe Passot; Denis Mulleman; Theodora Bejan-Angoulvant; Alexandre Aubourg; Stephanie Willot; Thierry Lecomte; Laurence Picon; Philippe Goupille; Gilles Paintaud; David Ternant
Journal:  MAbs       Date:  2016-08-09       Impact factor: 5.857

2.  Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.

Authors:  David Ternant; Christophe Passot; Alexandre Aubourg; Philippe Goupille; Céline Desvignes; Laurence Picon; Thierry Lecomte; Denis Mulleman; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 3.  Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Authors:  David Ternant; Nicolas Azzopardi; William Raoul; Theodora Bejan-Angoulvant; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

4.  Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.

Authors:  Paul R V Malik; Andrea N Edginton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-19

5.  Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

Authors:  Wannee Kantasiripitak; An Outtier; Sebastian G Wicha; Alexander Kensert; Zhigang Wang; João Sabino; Séverine Vermeire; Debby Thomas; Marc Ferrante; Erwin Dreesen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.